Atea Pharmaceuticals Stock Today

AVIR Stock  USD 2.94  0.01  0.34%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 6

 
High
 
Low
Low
Atea Pharmaceuticals is selling at 2.94 as of the 7th of December 2024; that is 0.34 percent increase since the beginning of the trading day. The stock's lowest day price was 2.87. Atea Pharmaceuticals has only a 6 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 14th of October 2023 and ending today, the 7th of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
30th of October 2020
Category
Healthcare
Classification
Health Care
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. The company has 84.46 M outstanding shares of which 2.64 M shares are presently shorted by private and institutional investors with about 15.03 trading days to cover. More on Atea Pharmaceuticals

Moving against Atea Stock

  0.65BMY Bristol Myers SquibbPairCorr
  0.48GILD Gilead SciencesPairCorr
  0.45WAT WatersPairCorr

Atea Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.210.41
Way Down
Slightly volatile
Gross Profit Margin0.80.9
Fairly Down
Slightly volatile
Total Current Liabilities57 M32.4 M
Way Up
Slightly volatile
Non Current Liabilities TotalM7.4 M
Notably Down
Slightly volatile
Total Assets541.8 M595 M
Significantly Down
Slightly volatile
Total Current Assets539.7 M590.5 M
Significantly Down
Slightly volatile
Debt Levels
Atea Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Atea Pharmaceuticals' financial leverage. It provides some insight into what part of Atea Pharmaceuticals' total assets is financed by creditors.
Liquidity
Atea Pharmaceuticals currently holds 2.4 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Atea Pharmaceuticals has a current ratio of 26.91, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Atea Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Other Cashflows From Financing Activities

244,150
Atea Pharmaceuticals (AVIR) is traded on NASDAQ Exchange in USA. It is located in 225 Franklin Street, Boston, MA, United States, 02110 and employs 75 people. Atea Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 247.48 M. Atea Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 84.46 M outstanding shares of which 2.64 M shares are presently shorted by private and institutional investors with about 15.03 trading days to cover. Atea Pharmaceuticals currently holds about 684.48 M in cash with (85.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Atea Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Atea Pharmaceuticals holds a total of 84.46 Million outstanding shares. The majority of Atea Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Atea Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Atea Pharmaceuticals. Please pay attention to any change in the institutional holdings of Atea Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Atea Ownership Details

Atea Stock Institutional Holders

InstituionRecorded OnShares
Dimensional Fund Advisors, Inc.2024-09-30
793.6 K
Northern Trust Corp2024-09-30
687.4 K
Charles Schwab Investment Management Inc2024-09-30
650.2 K
Citadel Advisors Llc2024-09-30
595.2 K
Two Sigma Advisers, Llc2024-09-30
582.4 K
Federated Hermes Inc2024-09-30
572.1 K
Jacobs Levy Equity Management, Inc.2024-09-30
509.5 K
Morgan Stanley - Brokerage Accounts2024-09-30
488.9 K
Newtyn Management Llc2024-09-30
380 K
Blackrock Inc2024-06-30
9.1 M
Bml Capital Management Llc2024-09-30
6.7 M
View Atea Pharmaceuticals Diagnostics

Atea Pharmaceuticals Historical Income Statement

At this time, Atea Pharmaceuticals' Total Other Income Expense Net is relatively stable compared to the past year. View More Fundamentals

Atea Stock Against Markets

Atea Pharmaceuticals Corporate Management

CPA CPAExec OfficerProfile
XiaoJian ZhouExecutive DevelopmentProfile
Jayanthi WolfExecutive AffairsProfile
Wayne CPAExecutive OfficerProfile
Ariyapadi KrishnarajVice MarketingProfile
JeanPierre SommadossiChairman, FounderProfile
John VavrickaChief OfficerProfile

Already Invested in Atea Pharmaceuticals?

The danger of trading Atea Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atea Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atea Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atea Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for Atea Stock Analysis

When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.